4.7 Review

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

期刊

KIDNEY INTERNATIONAL
卷 75, 期 12, 页码 1272-1277

出版社

ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2009.87

关键词

diabetes; glucose; glycosuria; hyperglycemia; kidney; transport

资金

  1. Forest Pharmaceuticals Inc
  2. GlaxoSmithKline
  3. National Institutes of Health
  4. AstraZeneca
  5. Eli Lilly and Company
  6. Daiichi Sankyo
  7. Novartis
  8. Novo-Nordisk
  9. Pfizer
  10. Sanofi-Aventis
  11. Takeda Pharmaceutical Company
  12. Abbott Laboratories
  13. Intermune Pharmaceutical

向作者/读者索取更多资源

The kidneys play a major role in the regulation of glucose in humans, reabsorbing 99% of the plasma glucose that filters through the renal glomeruli tubules. The glucose transporter, SGLT2, which is found primarily in the S1 segment of the proximal renal tubule, is essential to this process, accounting for 90% of the glucose reabsorption in the kidney. Evidence has suggested that selective inhibition of SGLT2 induces glucosuria in a dose-dependent manner and may have beneficial effects on glucose regulation in individuals with type II diabetes. Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects. Clinical research remains to be carried out on the long-term effects of glucosuria and other potential effects of this class of drug. Nonetheless, these compounds represent a very promising approach for the treatment of diabetes. Kidney International ( 2009) 75, 1272-1277; doi:10.1038/ki.2009.87; published online 8 April 2009

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据